13.-16.09.2016 - CAR-TCR Summit, Boston
2x Schendel
www.car-tcr-summit.com/about/agenda/
-
21.-22.09.2016 - Phacilitate, Berlin
www.cgteurope.com/Content/Immunotherapy-Europe/4/
-
21.09.2016
Baader Investment Conference
Präsentation erfolgt direkt mal durch unseren Helvea/Baader-Mann O.Zilian
www.baaderinvestmentconference.com/en/...conference_21_09_2016
-
NEU - Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference 25.09. – 28.09.2016 New York, USA
www.aacr.org/Meetings/Pages/...px?EventItemID=101#.V3tZvbiLS70
-
NEU - European Business Development Conference
27.09. – 28.09.2016 Frankfurt am Main
www.biodeutschland.org/ebdc2016.html
-
NEU - (Noch nicht auf der Homepage) ADOPTIVE T-CELL THERAPY SUMMIT 2016
10.10. - 11.10.2016 London
www.tcellsummit.com/
1. Mind the gap and fill the need: TCR cell therapies for patients with different MHCs and diverse forms of cancer
Benchmarking adoptive T cell therapies by the success of CD19-specific CAR T cell therapies for B cell malignancies, taking into account lingering B cell deficiencies in many clinical responders. A major gap is apparent if one looks beyond this success, due to limitations in surface antigens that can be used to target tumor cells without potentially causing damage to vital healthy tissues. TCR cell therapies hold the potential to fill this gap for both hematological cancers and solid tumors by their capacity to target tumor cells through an enormous variety of intracellular proteins, even including patient-specific neoantigens.
Using high-throughput and state-of-the-art technologies to prime T cells de novo to rapidly acquire optimal affinity TCRs specific for widely diverse intracellular proteins. The identified and isolated TCRs recognize specific epitopes presented by various HLA allotypes. By our proprietory technologies we are able to tailor TCRs for different patient groups, filling the gap for TCR therapies for MHC divergent patient populations suffering from diverse forms of cancer.
The use high-throughput platform technologies to acquire T cells specific for any selected combination of intracellular tumor-associated/specific antigen and HLA allotype.
Bypassing the need for pre-existing T cells responses in patients, giving us maximum flexibility to acquire TCRs of any desired specificity.
Technologies yield natural TCR sequences that display optimal functional avidity upon expression in T cells, without need for mutagenesis to improve TCR affinity.
TCR platform embodies state-of-the-art tools to assess TCR specificity, safety and pre-clinical efficacy using a combination of in silico, in vitro and ex vivo assessments.
Establishing automated approaches for rapid and efficient screening processes, opening the door to capture TCRs of individual patients specific for neoantigens.
Efficiently identify antigens and epitopes seen by T cells that reside in some patients and display tumor specificity. Access to TCRs of such T cells opens additional avenues of adoptive immunotherapy.
Prof Dolores Schendel - CEO & Chief Scientific Officer - Medigene
Zurück
Weiter
